The Malmberg lab partner in major cancer immunotherapy project
Karl-Johan Malmberg
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
From major journals, first or last author from the Institute for Cancer Research
Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM(2022) Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials J Immunother Cancer, 10(5) DOI 10.1136/jitc-2021-004345, PubMed 35613827
Skotland T, Iversen TG, Llorente A, Sandvig K(2022) Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges Adv Drug Deliv Rev, 186, 114326(in press) DOI 10.1016/j.addr.2022.114326, PubMed 35588953
Ianevski A, Giri AK, Aittokallio T(2022) SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples Nucleic Acids Res(in press) DOI 10.1093/nar/gkac382, PubMed 35580060
Smirnov P, Smith I, Safikhani Z, Ba-Alawi W, Khodakarami F, Lin E, Yu Y, Martin S, Ortmann J, Aittokallio T, Hafner M, Haibe-Kains B(2022) Evaluation of statistical approaches for association testing in noisy drug screening data BMC Bioinformatics, 23(1), 188 DOI 10.1186/s12859-022-04693-z, PubMed 35585485
Ianevski A, Giri AK, Aittokallio T(2022) SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples Nucleic Acids Res(in press) DOI 10.1093/nar/gkac382, PubMed 35580060
Kidd SG, Bogaard M, Carm KT, Bakken AC, Maltau AMV, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI(2022) In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis Mol Oncol(in press) DOI 10.1002/1878-0261.13225, PubMed 35574900